低度分化漿液性卵巢癌的治療

Treatment of Low-Grade Serous Ovarian Cancer

低度漿液性卵巢癌乃一不常見、組織學又很特別的癌症，並有高比例的KRAS和BRAF基因突變，並少有P53突變。治療方式主採減積手術切除病灶，再輔以platinum和taxane化學治療。如病灶復發，則可考慮予Bevacizumab合併其它化療；此外，荷爾蒙和MEK1/2抑制劑可能對有些病例有效，但仍需更多的研究來支持。

Low-grade serous ovarian cancer (LGSOC) is an uncommon but distinct histologic subtype of ovarian carcinoma. Mutations in KRAS and BRAF are prevalent in LGSOC, as P53 mutations are rare in LGSOC. The treatment includes surgical debulking followed by a combination of platinum/taxane-base chemotherapy. Bevacizumab, most often used in the combination of chemotherapy, has activity in recurrent LGSOC and should be considered a treatment option for these patients. Hormone therapy and mitogen-activated protein kinase kinase 1/2 (MEK 1/2) inhibitors have also demonstrated activity in some cases. Prospective clinical trials of these agents are warranted.